BRPI0814593A2 - Composto, composição farmacêutica que o contém e uso do composto. - Google Patents
Composto, composição farmacêutica que o contém e uso do composto.Info
- Publication number
- BRPI0814593A2 BRPI0814593A2 BRPI0814593-8A2A BRPI0814593A BRPI0814593A2 BR PI0814593 A2 BRPI0814593 A2 BR PI0814593A2 BR PI0814593 A BRPI0814593 A BR PI0814593A BR PI0814593 A2 BRPI0814593 A2 BR PI0814593A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- composition containing
- pharmaceutical
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007052991 | 2007-07-27 | ||
| PCT/IB2008/052989 WO2009016564A2 (en) | 2007-07-27 | 2008-07-25 | 2-aza-bicyclo[3.3.0]octane derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814593A2 true BRPI0814593A2 (pt) | 2015-01-20 |
Family
ID=40174799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814593-8A2A BRPI0814593A2 (pt) | 2007-07-27 | 2008-07-25 | Composto, composição farmacêutica que o contém e uso do composto. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8288429B2 (pt) |
| EP (1) | EP2183246A2 (pt) |
| JP (1) | JP2010534647A (pt) |
| KR (1) | KR20100046047A (pt) |
| CN (1) | CN101874028B (pt) |
| AU (1) | AU2008281399A1 (pt) |
| BR (1) | BRPI0814593A2 (pt) |
| CA (1) | CA2693820A1 (pt) |
| MA (1) | MA31593B1 (pt) |
| NZ (1) | NZ583487A (pt) |
| RU (1) | RU2478099C2 (pt) |
| WO (1) | WO2009016564A2 (pt) |
| ZA (1) | ZA201001434B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE481383T1 (de) * | 2006-09-29 | 2010-10-15 | Actelion Pharmaceuticals Ltd | 3-aza-bicycloä3.1.0ühexanderivate |
| DE602007012142D1 (en) | 2006-12-01 | 2011-03-03 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
| CL2007003827A1 (es) * | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| CL2008000836A1 (es) * | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| AU2008260647A1 (en) | 2007-05-23 | 2008-12-11 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| AU2008272449A1 (en) * | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
| WO2009040730A2 (en) * | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| ATE555107T1 (de) * | 2008-02-21 | 2012-05-15 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo-ä2,2,1-üheptan-derivate |
| KR20100135962A (ko) * | 2008-04-30 | 2010-12-27 | 액테리온 파마슈티칼 리미티드 | 피페리딘 및 피롤리딘 화합물 |
| MX2011003191A (es) * | 2008-10-14 | 2011-04-27 | Actelion Pharmaceuticals Ltd | Derivados de fenetilamida y sus analogos heterociclicos. |
| SI2491038T1 (sl) | 2009-10-23 | 2016-08-31 | Janssen Pharmaceutica N.V. | Disubstituirani oktahil-dropirolo(3,4-c)piroli kot modulatorji oreksinskega receptorja |
| MX2012006909A (es) * | 2009-12-29 | 2012-07-10 | Suven Life Sciences Ltd | LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA. |
| US8173808B2 (en) | 2009-12-30 | 2012-05-08 | Arqule, Inc. | Substituted naphthalenyl-pyrimidine compounds |
| HK1204955A1 (zh) | 2012-02-07 | 2015-12-11 | Eolas Therapeutics Inc. | 取代的脯氨酸/哌啶用作食慾素受體拮抗劑 |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| ITMI20120424A1 (it) | 2012-03-19 | 2013-09-20 | Rottapharm Spa | Composti chimici |
| KR101689093B1 (ko) | 2012-06-04 | 2016-12-22 | 액테리온 파마슈티칼 리미티드 | 벤즈이미다졸-프롤린 유도체 |
| JP6244365B2 (ja) | 2012-10-10 | 2017-12-06 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| WO2015083070A1 (en) | 2013-12-03 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| MX366642B (es) | 2013-12-04 | 2019-07-17 | Idorsia Pharmaceuticals Ltd | Uso de derivados de bencimidazol-prolina. |
| US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
| SMT202200323T1 (it) | 2016-02-12 | 2022-09-14 | Astrazeneca Ab | Piperidine alo-sostituite come modulatori del recettore di oressina |
| PH12018501903B1 (en) | 2016-03-10 | 2023-03-17 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| EP3454857A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
| GB201618181D0 (en) | 2016-10-27 | 2016-12-14 | J Banks & Co Ltd | Slide turn door assembly and support mechanism therefor |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| EP4199925A4 (en) * | 2020-08-18 | 2024-08-28 | Merck Sharp & Dohme LLC | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS |
| TW202400149A (zh) | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57139032A (en) | 1981-02-20 | 1982-08-27 | Takasago Corp | 2-(butan-2-on-3-yl)-5-methylphenol and perfumery composition containing the same |
| IT1231413B (it) * | 1987-09-23 | 1991-12-04 | Angeli Inst Spa | Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht |
| DE4243287A1 (de) * | 1992-06-19 | 1993-12-23 | Basf Ag | N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| GB9319732D0 (en) | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| WO1995029922A1 (en) | 1994-04-29 | 1995-11-09 | Pharmacia & Upjohn Company | Methanol derivatives for treatment of retroviral infections especially hiv infections |
| WO2001096302A1 (en) | 2000-06-16 | 2001-12-20 | Smithkline Beecham P.L.C. | Piperidines for use as orexin receptor antagonists |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| AU2002224885A1 (en) * | 2000-11-28 | 2002-06-11 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| EP1435955A2 (en) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| AR033306A1 (es) | 2001-05-05 | 2003-12-10 | Smithkline Beecham Plc | Compuestos |
| MXPA03011706A (es) | 2001-06-28 | 2004-03-19 | Smithkline Beecham Plc | Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina. |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| EP1539747B1 (en) | 2002-09-18 | 2006-11-02 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| CZ2005252A3 (cs) | 2002-09-25 | 2005-11-16 | Memory Pharmaceuticals Corporation | Indazoly, benzothiazoly a benzoisothiazoly jejich příprava a použití |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| EP1735306A2 (en) | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| US20060014733A1 (en) | 2004-07-19 | 2006-01-19 | Pfizer Inc | Histamine-3 agonists and antagonists |
| ATE481383T1 (de) | 2006-09-29 | 2010-10-15 | Actelion Pharmaceuticals Ltd | 3-aza-bicycloä3.1.0ühexanderivate |
| DE602007012142D1 (en) | 2006-12-01 | 2011-03-03 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| DE602008002934D1 (de) | 2007-05-14 | 2010-11-18 | Actelion Pharmaceuticals Ltd | 2-cyclopropylthiazolderivate |
| AU2008260647A1 (en) | 2007-05-23 | 2008-12-11 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| CN101679366B (zh) | 2007-05-23 | 2013-08-07 | 默沙东公司 | 吡啶基哌啶食欲素受体拮抗剂 |
| CL2008001951A1 (es) | 2007-07-03 | 2009-01-09 | Glaxo Group Ltd | Compuestos derivados de imidazo[1,2-a]pirimidin-2-ilmetil sustituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el trastorno del sueno, depresion, ansiedad, trastorno relacionado con el abuso de sustancias, entre otras. |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
| WO2009040730A2 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| BRPI0821141A2 (pt) | 2007-12-21 | 2015-06-16 | Hoffmann La Roche | Derivados de heteroarila como antagonistas do receptor de orexina |
| ATE555107T1 (de) | 2008-02-21 | 2012-05-15 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo-ä2,2,1-üheptan-derivate |
| KR20100135962A (ko) | 2008-04-30 | 2010-12-27 | 액테리온 파마슈티칼 리미티드 | 피페리딘 및 피롤리딘 화합물 |
| US8674093B2 (en) | 2008-05-22 | 2014-03-18 | Merck Canada Inc. | Process for the preparation of an orexin receptor antagonist |
-
2008
- 2008-07-25 AU AU2008281399A patent/AU2008281399A1/en not_active Abandoned
- 2008-07-25 RU RU2010106854/04A patent/RU2478099C2/ru not_active IP Right Cessation
- 2008-07-25 NZ NZ583487A patent/NZ583487A/en not_active IP Right Cessation
- 2008-07-25 EP EP08789443A patent/EP2183246A2/en not_active Withdrawn
- 2008-07-25 CA CA2693820A patent/CA2693820A1/en not_active Abandoned
- 2008-07-25 BR BRPI0814593-8A2A patent/BRPI0814593A2/pt not_active IP Right Cessation
- 2008-07-25 WO PCT/IB2008/052989 patent/WO2009016564A2/en not_active Ceased
- 2008-07-25 CN CN200880100389XA patent/CN101874028B/zh not_active Expired - Fee Related
- 2008-07-25 JP JP2010517536A patent/JP2010534647A/ja active Pending
- 2008-07-25 KR KR1020107004524A patent/KR20100046047A/ko not_active Withdrawn
- 2008-07-25 US US12/670,823 patent/US8288429B2/en not_active Expired - Fee Related
-
2010
- 2010-02-05 MA MA32589A patent/MA31593B1/fr unknown
- 2010-02-26 ZA ZA2010/01434A patent/ZA201001434B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ583487A (en) | 2011-09-30 |
| JP2010534647A (ja) | 2010-11-11 |
| CN101874028A (zh) | 2010-10-27 |
| WO2009016564A2 (en) | 2009-02-05 |
| RU2478099C2 (ru) | 2013-03-27 |
| RU2010106854A (ru) | 2011-09-10 |
| MA31593B1 (fr) | 2010-08-02 |
| KR20100046047A (ko) | 2010-05-04 |
| WO2009016564A3 (en) | 2009-03-26 |
| CA2693820A1 (en) | 2009-02-05 |
| US8288429B2 (en) | 2012-10-16 |
| US20110009461A1 (en) | 2011-01-13 |
| AU2008281399A1 (en) | 2009-02-05 |
| ZA201001434B (en) | 2013-08-28 |
| EP2183246A2 (en) | 2010-05-12 |
| CN101874028B (zh) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
| BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
| BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
| BRPI0716171A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto. | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| CL2007002916A1 (es) | Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras. | |
| BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
| BRPI0818804A2 (pt) | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. | |
| BRPI0809977A2 (pt) | Uso de um composto, compostos e composição farmacêutica que o contém | |
| BRPI0815190A2 (pt) | Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo | |
| BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0815079A2 (pt) | Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto | |
| BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
| BRPI0922435A2 (pt) | "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso." | |
| BRPI0813341A2 (pt) | " uso de compostos, composições curáveis, e, uso de composições curáveis ". | |
| CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
| BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI0609802A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI0810399A2 (pt) | Composto, composição farmacêutica que o contém e uso do mesmo | |
| BRPI0821004A2 (pt) | Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste | |
| BRPI0907892A2 (pt) | Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo | |
| BRPI0908208A2 (pt) | Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |